{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:08:45Z","timestamp":1790035725046,"version":"4.0.1"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cellsig.2026.112367","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:02:04Z","timestamp":1768582924000},"page":"112367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cellular signaling and radioresistance in prostate cancer"],"prefix":"10.1016","volume":"141","author":[{"given":"Gustavo A.","family":"Sosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Crosswhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin N.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2023","key":"10.1016\/j.cellsig.2026.112367_bb0005","first-page":"191","article-title":"Update on prostate Cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0010","author":"Key Statistics for Prostate Cancer | Prostate Cancer Facts"},{"key":"10.1016\/j.cellsig.2026.112367_bb0015","doi-asserted-by":"crossref","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cellsig.2026.112367_bb0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2012.02.014","article-title":"DNA-PKcs expression predicts response to radiotherapy in prostate cancer","volume":"84","author":"Bouchaert","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellsig.2026.112367_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13148-021-01111-8","article-title":"Epigenetic mechanisms underlying prostate cancer radioresistance","volume":"13","author":"Macedo-Silva","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.cellsig.2026.112367_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156980","article-title":"ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer","volume":"193","author":"van Campen","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.cellsig.2026.112367_bb0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","article-title":"Profiles of Radioresistance mechanisms in prostate Cancer","volume":"23","author":"Chaiswing","year":"2018","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.cellsig.2026.112367_bb0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellsig.2026.112367_bb0050","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/pros.23435","article-title":"Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance","volume":"77","author":"Stark","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.cellsig.2026.112367_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060408","article-title":"PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells","volume":"8","author":"Chatterjee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2026.112367_bb0060","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate Cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112367_bb0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.cellsig.2026.112367_bb0070","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"TRITON3 investigators, Rucaparib or physician\u2019s choice in metastatic prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112367_bb0075","first-page":"3339","article-title":"MAGNITUDE principal investigators, Niraparib and Abiraterone acetate for metastatic castration-resistant prostate Cancer, J. Clin. Oncol. Off. J. Am. Soc","volume":"41","author":"Chi","year":"2023","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0085","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1074\/jbc.M410873200","article-title":"Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage","volume":"280","author":"Helt","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2026.112367_bb0090","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.3390\/ijms21218273","article-title":"Targeting DNA damage response in prostate and breast Cancer","volume":"21","author":"Wengner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellsig.2026.112367_bb0095","doi-asserted-by":"crossref","first-page":"23262","DOI":"10.1074\/jbc.M503701200","article-title":"Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis","volume":"280","author":"Truman","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2026.112367_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccell.2015.06.004","article-title":"DNA-PKcs mediated transcriptional regulation drives prostate cancer progression and metastasis","volume":"28","author":"Goodwin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0105","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/2159-8290.CD-14-0358","article-title":"Beyond DNA repair: DNA-PK function in cancer","volume":"4","author":"Goodwin","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112367_bb0110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2016.02.015","article-title":"DNA-PKcs expression is a predictor of biochemical recurrence after permanent iodine 125 interstitial brachytherapy for prostate Cancer","volume":"95","author":"Molina","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellsig.2026.112367_bb0115","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112367_bb0120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2559.2009.03448.x","article-title":"Overexpression of RAD51 occurs in aggressive prostatic cancer","volume":"55","author":"Mitra","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.cellsig.2026.112367_bb0125","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1128\/MCB.24.21.9305-9316.2004","article-title":"Genetic steps of mammalian homologous repair with distinct mutagenic consequences","volume":"24","author":"Stark","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0130","first-page":"1113","article-title":"Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers","volume":"28","author":"Connell","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0135","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4","article-title":"Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer","volume":"88","author":"Maacke","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellsig.2026.112367_bb0140","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1021\/bi00769a018","article-title":"Rate of depurination of native deoxyribonucleic acid","volume":"11","author":"Lindahl","year":"1972","journal-title":"Biochemistry"},{"key":"10.1016\/j.cellsig.2026.112367_bb0145","first-page":"2522","article-title":"Endogenous apurinic\/apyrimidinic sites in genomic DNA of mammalian tissues","volume":"59","author":"Nakamura","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0150","first-page":"824","article-title":"Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1\/ref-1 in prostate cancer","volume":"7","author":"Kelley","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0155","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s11033-010-0267-z","article-title":"Base excision repair genes XRCC1 and APEX1 and the risk for prostate cancer","volume":"38","author":"Kuasne","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cellsig.2026.112367_bb0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00438-014-0916-3","article-title":"The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case-control studies","volume":"290","author":"Zhou","year":"2015","journal-title":"Mol. Genet. Genomics MGG"},{"key":"10.1016\/j.cellsig.2026.112367_bb0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0022-5347(05)00042-X","article-title":"Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans","volume":"175","author":"Chen","year":"2006","journal-title":"J. Urol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0170","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/mc.22670","article-title":"Apurinic\/apyrimidinic endonuclease 1 (APE1\/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion","volume":"56","author":"Juhnke","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.cellsig.2026.112367_bb0175","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1158\/1078-0432.CCR-18-2387","article-title":"DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway","volume":"25","author":"Kothari","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc Cancer Res."},{"issue":"111","key":"10.1016\/j.cellsig.2026.112367_bb0180","first-page":"e15","article-title":"Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer","volume":"35","author":"Zhang","year":"2017","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020311","article-title":"Targeting the DNA double strand break repair machinery in prostate cancer","volume":"6","author":"Shaheen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2026.112367_bb0190","first-page":"1446","article-title":"A novel role for DNA-PK in metabolism by regulating glycolysis in castration-resistant prostate Cancer, Clin. Cancer res. Off. J. Am. Assoc","volume":"28","author":"Dylgjeri","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0195","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0200","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-03-3499","article-title":"Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade","volume":"64","author":"Li","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0205","first-page":"1917","article-title":"STAT5A\/B blockade sensitizes prostate Cancer to radiation through inhibition of RAD51 and DNA repair, Clin. Cancer res. Off. J. Am. Assoc","volume":"24","author":"Maranto","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0210","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.23273","article-title":"Simvastatin up-regulates Annexin A10 that can inhibit the proliferation, migration, and invasion in androgen-independent human prostate Cancer cells","volume":"77","author":"Miyazawa","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.cellsig.2026.112367_bb0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21873\/anticanres.16791","article-title":"Simvastatin enhances the Radiosensitivity of androgen-independent prostate Cancer cells via inhibition of RAD51 expression","volume":"44","author":"Oka","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0220","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.18632\/oncotarget.23493","article-title":"APE1\/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells","volume":"9","author":"McIlwain","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellsig.2026.112367_bb0225","doi-asserted-by":"crossref","first-page":"533","DOI":"10.62713\/aic.3946","article-title":"Clinical study on thromboembolic events in prostate Cancer patients receiving radiation therapy with or without androgen deprivation therapy","volume":"96","author":"Huangfu","year":"2025","journal-title":"Ann. Ital. Chir."},{"key":"10.1016\/j.cellsig.2026.112367_bb0230","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"MARCAP consortium group, androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0235","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112367_bb0240","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/2159-8290.CD-13-0679","article-title":"Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer","volume":"3","author":"Bartek","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112367_bb0245","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1158\/0008-5472.CAN-15-0892","article-title":"Androgen receptor upregulation mediates Radioresistance after ionizing radiation","volume":"75","author":"Spratt","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0250","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.3390\/ijms23094786","article-title":"Androgen receptor gene pathway upregulation and radiation resistance in Oligometastatic prostate Cancer","volume":"23","author":"Saxby","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellsig.2026.112367_bb0255","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0260","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1158\/0008-5472.CAN-17-0164","article-title":"Androgen receptor variants mediate DNA repair after prostate Cancer irradiation","volume":"77","author":"Yin","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0265","doi-asserted-by":"crossref","first-page":"22112","DOI":"10.1074\/jbc.M112.357384","article-title":"Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer","volume":"287","author":"Mahajan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2026.112367_bb0270","doi-asserted-by":"crossref","first-page":"e17084","DOI":"10.1200\/JCO.2023.41.16_suppl.e17084","article-title":"Relationship between androgen biosynthesis linked to 3\u03b2HSD1 and resistance to radiotherapy: a germline biomarker for combined androgen blockade with radiation in high-risk prostate cancer","volume":"41","author":"Ganguly","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0275","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/pros.23135","article-title":"The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma","volume":"76","author":"Paximadis","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.cellsig.2026.112367_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214670","article-title":"Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway","volume":"14","author":"Sekhar","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2026.112367_bb0285","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/jcm11195637","article-title":"Drivers of Radioresistance in prostate Cancer","volume":"11","author":"King","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cellsig.2026.112367_bb0290","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2353\/ajpath.2009.080727","article-title":"NF-\u03baB regulates androgen receptor expression and prostate Cancer growth","volume":"175","author":"Zhang","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0295","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.37349\/etat.2024.00266","article-title":"Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies","volume":"5","author":"Thakur","year":"2024","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"10.1016\/j.cellsig.2026.112367_bb0300","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1953","article-title":"Integration of EGFR inhibitors with radiochemotherapy","volume":"6","author":"Nyati","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112367_bb0305","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2015.07.003","article-title":"Phosphatidylinositol 3-kinase\/Akt signaling as a key mediator of tumor cell responsiveness to radiation","volume":"35","author":"Toulany","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0310","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.critrevonc.2015.07.005","article-title":"Targeting PI3K\/Akt\/mTOR signaling pathway in the treatment of prostate cancer radioresistance","volume":"96","author":"Chang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0315","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.biocel.2013.09.008","article-title":"Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo\/radioresistance via the PI3K\/Akt\/mTOR signaling pathway","volume":"45","author":"Ni","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.407","article-title":"Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K\/Akt\/mTOR pathway in prostate cancer radioresistance","volume":"4","author":"Chang","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellsig.2026.112367_bb0325","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10555-014-9493-5","article-title":"Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy","volume":"33","author":"Chang","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.cellsig.2026.112367_bb0330","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/path.2559","article-title":"PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer","volume":"218","author":"Sircar","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0335","first-page":"703","article-title":"Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas","volume":"23","author":"de Muga","year":"2010","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc"},{"key":"10.1016\/j.cellsig.2026.112367_bb0340","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1126\/science.279.5351.710","article-title":"Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B","volume":"279","author":"Stephens","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2026.112367_bb0345","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0960-9822(06)00336-8","article-title":"3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase","volume":"7","author":"Alessi","year":"1997","journal-title":"Curr. Biol. CB"},{"key":"10.1016\/j.cellsig.2026.112367_bb0350","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.cellsig.2026.112367_bb0355","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0360","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.cellsig.2026.112367_bb0365","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1073\/pnas.1302455110","article-title":"Feature article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology","volume":"110","author":"Betz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellsig.2026.112367_bb0370","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1002\/pmic.200800113","article-title":"Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells","volume":"8","author":"Skvortsova","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.cellsig.2026.112367_bb0375","article-title":"Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS\/MS proteomic approach","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2026.112367_bb0380","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ijrobp.2005.08.014","article-title":"Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism","volume":"63","author":"Gottschalk","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellsig.2026.112367_bb0385","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2012.11.014","article-title":"Radiosensitization of prostate cancer cells by the dual PI3K\/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions, Radiother. Oncol. J. Eur. Soc. Ther","volume":"106","author":"Potiron","year":"2013","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0390","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/1878-0261.13577","article-title":"Dual targeting of the androgen receptor and PI3K\/AKT\/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis","volume":"18","author":"Sugawara","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111846","article-title":"Deciphering JAK\/STAT signaling pathway: a multifaceted approach to tumorigenesis, progression and therapeutic interventions","volume":"131","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0400","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112367_bb0405","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0410","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1756-8722-6-90","article-title":"STAT inhibitors for cancer therapy, J. Hematol. Oncol","volume":"6","author":"Furqan","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0415","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jrr\/rrab117","article-title":"STAT3 as a target for sensitizing prostate cancer cells to irradiation","volume":"63","author":"Zhang","year":"2022","journal-title":"J. Radiat. Res. (Tokyo)"},{"key":"10.1016\/j.cellsig.2026.112367_bb0420","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/cancers6020829","article-title":"The multifaceted roles of STAT3 signaling in the progression of prostate Cancer","volume":"6","author":"Bishop","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2026.112367_bb0425","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.bjc.6603871","article-title":"Expression levels of the JAK\/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer","volume":"97","author":"Tam","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellsig.2026.112367_bb0430","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellsig.2026.112367_bb0435","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/biomedicines11061628","article-title":"Uncovering the secrets of prostate cancer\u2019s radiotherapy resistance: advances in mechanism research","volume":"11","author":"Lyu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.cellsig.2026.112367_bb0440","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semradonc.2004.04.008","article-title":"Tumor microenvironmental physiology and its implications for radiation oncology","volume":"14","author":"Vaupel","year":"2004","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0445","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cellsig.2026.112367_bb0450","first-page":"6054","article-title":"Hypoxia-inducible Factor-1: a novel therapeutic target for the management of cancer","volume":"14","author":"Bui","year":"2022","journal-title":"Drug Resistance, and Cancer-Related Pain, Cancers"},{"key":"10.1016\/j.cellsig.2026.112367_bb0455","first-page":"5192","article-title":"Targeting HIF-1\u03b1 by natural and synthetic compounds: a promising approach for anti-Cancer therapeutics development","volume":"27","author":"Ghosh","year":"2022","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.cellsig.2026.112367_bb0460","first-page":"2108","article-title":"Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer, Clin. Cancer res. Off. J. Am. Assoc","volume":"18","author":"Milosevic","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0465","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ncpuro0434","article-title":"Mechanisms of disease: angiogenesis in urologic malignancies","volume":"3","author":"Charlesworth","year":"2006","journal-title":"Nat. Clin. Pract. Urol."},{"issue":"744","key":"10.1016\/j.cellsig.2026.112367_bb0470","first-page":"e17","article-title":"Effect of small interfering RNA targeting hypoxia-inducible factor-1\u03b1 on radiosensitivity of PC3 cell line","volume":"79","author":"Huang","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.cellsig.2026.112367_bb0475","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/OTT.S158206","article-title":"The role of HIF-1\u03b1 in chemo\u2212\/radioresistant tumors","volume":"11","author":"Xia","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cellsig.2026.112367_bb0480","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1535-6108(04)00115-1","article-title":"Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules","volume":"5","author":"Moeller","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102961","article-title":"The role of epithelial-mesenchymal transition in regulating radioresistance","volume":"150","author":"Zhou","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0490","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-3173","article-title":"Molecular pathways: linking tumor microenvironment to epithelial\u2013mesenchymal transition in metastasis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0495","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0500","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1464-410X.2012.11551.x","article-title":"Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy","volume":"111","author":"Behnsawy","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.cellsig.2026.112367_bb0505","first-page":"90","article-title":"Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis","volume":"3","author":"Sethi","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0510","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12967-025-06422-5","article-title":"Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges","volume":"23","author":"Xie","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cellsig.2026.112367_bb0515","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.canlet.2019.08.020","article-title":"Cancer stem cells in prostate cancer radioresistance","volume":"465","author":"Tsao","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellsig.2026.112367_bb0520","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.semcancer.2018.05.001","article-title":"Cancer stem cells: regulation programs, immunological properties and immunotherapy","volume":"52","author":"Zhang","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0525","first-page":"5692","article-title":"Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma, Clin. Cancer res. Off. J. Am. Assoc","volume":"16","author":"Dubrovska","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0530","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/pros.22775","article-title":"CD44 variant 6 is associated with prostate cancer metastasis and chemo\u2212\/radioresistance","volume":"74","author":"Ni","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.cellsig.2026.112367_bb0535","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde dehydrogenase is regulated by \u03b2-catenin\/TCF and promotes Radioresistance in prostate Cancer progenitor cells","volume":"75","author":"Cojoc","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0540","first-page":"5830","article-title":"Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells","volume":"17","author":"Murata","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cellsig.2026.112367_bb0545","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1349-7006.2009.01174.x","article-title":"Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer","volume":"100","author":"Shimada","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellsig.2026.112367_bb0550","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/pros.22527","article-title":"Long-term recovery of irradiated prostate cancer increases cancer stem cells","volume":"72","author":"Cho","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.cellsig.2026.112367_bb0555","first-page":"4469","article-title":"Low production of reactive oxygen species and high DNA repair: mechanism of radioresistance of prostate cancer stem cells","volume":"33","author":"Kim","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0560","first-page":"176","article-title":"c-FLIP, a master anti-apoptotic regulator","volume":"34","author":"Safa","year":"2012","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0565","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bcp.2010.04.010","article-title":"Apoptosis and cancer stem cells: implications for apoptosis targeted therapy","volume":"80","author":"Kruyt","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0570","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jmcb\/mjr002","article-title":"SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell","volume":"3","author":"Jia","year":"2011","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1410102","article-title":"Prostate cancer stem cells and their targeted therapies","volume":"12","author":"Su","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104705","article-title":"Interactions between radiotherapy resistance mechanisms and the tumor microenvironment","volume":"210","author":"Li","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0585","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.3390\/cancers16213685","article-title":"Deciphering the tumor microenvironment in prostate Cancer: a focus on the stromal component","volume":"16","author":"Pakula","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2026.112367_bb0590","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1158\/0008-5472.CAN-10-0785","article-title":"Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness","volume":"70","author":"Giannoni","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0595","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3892\/ijo.2015.3060","article-title":"BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts","volume":"47","author":"Wen","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0600","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030510","article-title":"Cellular constituents of the prostate stroma: key contributors to prostate Cancer progression and therapy resistance","volume":"8","author":"Levesque","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.cellsig.2026.112367_bb0605","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112367_bb0610","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2353\/ajpath.2009.080501","article-title":"Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing","volume":"174","author":"Bharadwaj","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0615","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-011-9340-x","article-title":"Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression","volume":"31","author":"Cirri","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.cellsig.2026.112367_bb0620","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","article-title":"Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses","volume":"14","author":"Hirz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112367_bb0625","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2174\/1389450120666190123141553","article-title":"A review of preclinical experiments toward targeting M2 macrophages in prostate Cancer","volume":"20","author":"Seif","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cellsig.2026.112367_bb0630","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.cellsig.2026.112367_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106807","article-title":"The interactions and communications in tumor resistance to radiotherapy: therapy perspectives","volume":"87","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0640","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","article-title":"Radiation-induced amphiregulin drives tumour metastasis","volume":"643","author":"Piffk\u00f3","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112367_bb0645","article-title":"Amphiregulin as a mediator of radiation-induced systemic effects in metastatic Cancer: balancing local control with distant progression, Clin. Cancer res. Off. J. Am. Assoc","author":"Piffk\u00f3","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0650","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ccell.2025.06.008","article-title":"The dark side of radiotherapy","volume":"43","author":"Piffk\u00f3","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112367_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112377","article-title":"Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells","volume":"42","author":"Steiner","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2026.112367_bb0660","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO-25-00274","article-title":"Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate Cancer: 10-year outcomes of the FLAME trial","volume":"43","author":"Menne Guricov\u00e1","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0665","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-99286-0_2","article-title":"Advances in radiotherapy for prostate Cancer treatment","volume":"1096","author":"Podder","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0670","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semradonc.2025.04.004","article-title":"Hypofractionation\/ultra-hypofractionation for prostate Cancer radiotherapy","volume":"35","author":"Chakrabarti","year":"2025","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0675","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112367_bb0680","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.semradonc.2023.03.009","article-title":"Hypoxia-targeted dose painting in radiotherapy","volume":"33","author":"Salem","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0685","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellsig.2026.112367_bb0690","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2020.01.023","article-title":"MRI-guided Ultrafocal salvage high-dose-rate brachytherapy for localized Radiorecurrent prostate Cancer: updated results of 50 patients","volume":"107","author":"van Son","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellsig.2026.112367_bb0695","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.3390\/cancers15245735","article-title":"Clinical use of a commercial artificial intelligence-based software for autocontouring in radiation therapy: geometric performance and Dosimetric impact","volume":"15","author":"Hoque","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2026.112367_bb0700","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate Cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0705","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2023.07.029","article-title":"Assessing the feasibility of using artificial intelligence-segmented dominant Intraprostatic lesion for focal Intraprostatic boost with external beam radiation therapy","volume":"118","author":"Tsui","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cellsig.2026.112367_bb0710","first-page":"33","article-title":"Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study","volume":"12","author":"Shi","year":"2025","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.cellsig.2026.112367_bb0715","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1200\/JCO.2023.41.6_suppl.393","article-title":"Long-term rates of biochemical recurrence after primary external beam radiation therapy (EBRT) for prostate cancer","volume":"41","author":"Escobar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0720","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS351","article-title":"Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer","volume":"42","author":"Myint","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112367_bb0725","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A phase I study of combination Olaparib and Radium-223 in men with metastatic castration-resistant prostate Cancer (mCRPC) with bone metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellsig.2026.112367_bb0730","unstructured":"Mayo Clinic, MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer, clinicaltrials.gov, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06378866 (accessed October 27, 2025)."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:44:21Z","timestamp":1776825861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":146,"alternative-id":["S0898656826000161"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112367","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular signaling and radioresistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112367"}}